Half-Year 2022 Financial and Clinical Trials Update
Lunsumio (mosunetuzumab, CD20 x CD3, RG7828)
Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously
Indication
2L+ FL
Relapsed or refractory FL
Relapsed or refractory CLL
Phase/study
# of patients
Phase III
CELESTIMO
Phase Ib/II
Phase Ib/II
N=400
N=118
▪ ARM A: Lunsumio plus lenalidomide
▪ ARM B: Rituxan plus lenalidomide
▪ ARM A: Lunsumio plus tiragolumab
Design
▪ ARM B: Lunsumio plus tiragolumab plus
Tecentriq
■ Dose escalation phase
Dose expansion phase
N=56
Lunsumio monotherapy (3L+ CLL)
▪ Progression-free survival
"
Phase Ib: Dose-limiting toxicity
Primary endpoint
Phase II: Best complete response
Status
CT Identifier
FPI Q4 2021
NCT04712097
FPI Phase lb Q2 2022
NCT05315713
FL=follicular lymphoma; r/r=relapsed/refractory; RPTD=Recommended Phase II Dose; CLL=Chronic lymphocytic leukemia
■ Safety, dose-limiting toxicity and RPTD
■ FPI Q1 2022
104
Roche
OncologyView entire presentation